UniQure Pays US$10 M Upfront for Apic Bio’s ALS Gene Therapy
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 2 (Table of Contents)
Published: 15 Feb-2023
DOI: 10.3833/pdr.v2023.i2.2766 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Adding another gene therapy to its portfolio, uniQure has entered into a licensing agreement with Apic Bio for APB-102, a one-time gene therapy for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS